quinidine

Ligand id: 2342

Name: quinidine

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 3
Hydrogen bond donors 1
Rotatable bonds 4
Topological polar surface area 45.59
Molecular weight 324.18
XLogP 2.66
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

References
1. Bardien-Kruger S, Wulff H, Arieff Z, Brink P, Chandy KG, Corfield V. (2002)
Characterisation of the human voltage-gated potassium channel gene, KCNA7, a candidate gene for inherited cardiac disorders, and its exclusion as cause of progressive familial heart block I (PFHBI).
Eur. J. Hum. Genet.10 (1): 36-43. [PMID:11896454]
2. Bhattacharjee A, Joiner WJ, Wu M, Yang Y, Sigworth FJ, Kaczmarek LK. (2003)
Slick (Slo2.1), a rapidly-gating sodium-activated potassium channel inhibited by ATP.
J. Neurosci.23 (37): 11681-91. [PMID:14684870]
3. Caballero R, Pourrier M, Schram G, Delpón E, Tamargo J, Nattel S. (2003)
Effects of flecainide and quinidine on Kv4.2 currents: voltage dependence and role of S6 valines.
Br. J. Pharmacol.138 (8): 1475-84. [PMID:12721103]
4. Engel K, Wang J. (2005)
Interaction of organic cations with a newly identified plasma membrane monoamine transporter.
Mol. Pharmacol.68 (5): 1397-407. [PMID:16099839]
5. Gessner G, Zacharias M, Bechstedt S, Schönherr R, Heinemann SH. (2004)
Molecular determinants for high-affinity block of human EAG potassium channels by antiarrhythmic agents.
Mol. Pharmacol.65 (5): 1120-9. [PMID:15102940]
6. Hill RJ, Duff HJ, Sheldon RS. (1989)
Class I antiarrhythmic drug receptor: biochemical evidence for state-dependent interaction with quinidine and lidocaine.
Mol. Pharmacol.36 (1): 150-9. [PMID:2546048]
7. Milligan CJ, Li M, Gazina EV, Heron SE, Nair U, Trager C, Reid CA, Venkat A, Younkin DP, Dlugos DJ et al.. (2014)
KCNT1 gain of function in 2 epilepsy phenotypes is reversed by quinidine.
Ann. Neurol.75 (4): 581-90. [PMID:24591078]
8. Schönherr R, Gessner G, Löber K, Heinemann SH. (2002)
Functional distinction of human EAG1 and EAG2 potassium channels.
FEBS Lett.514 (2-3): 204-8. [PMID:11943152]
9. Sheldon RS, Duff HJ, Thakore E, Hill RJ. (1994)
Class I antiarrhythmic drugs: allosteric inhibitors of [3H] batrachotoxinin binding to rat cardiac sodium channels.
J. Pharmacol. Exp. Ther.268 (1): 187-94. [PMID:8301556]
10. Snyders J, Knoth KM, Roberds SL, Tamkun MM. (1992)
Time-, voltage-, and state-dependent block by quinidine of a cloned human cardiac potassium channel.
Mol. Pharmacol.41 (2): 322-30. [PMID:1538710]
11. Sánchez-Carranza O, Torres-Rodríguez P, Darszon A, Treviño CL, López-González I. (2015)
Pharmacology of hSlo3 channels and their contribution in the capacitation-associated hyperpolarization of human sperm.
Biochem. Biophys. Res. Commun.466 (3): 554-9. [PMID:26381170]
12. Tang QY, Zhang Z, Xia XM, Lingle CJ. (2010)
Block of mouse Slo1 and Slo3 K+ channels by CTX, IbTX, TEA, 4-AP and quinidine.
Channels (Austin)4 (1): 22-41. [PMID:19934650]
13. Tanihara Y, Masuda S, Sato T, Katsura T, Ogawa O, Inui K. (2007)
Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters.
Biochem. Pharmacol.74 (2): 359-71. [PMID:17509534]
14. Wang J. (2016)
The plasma membrane monoamine transporter (PMAT): Structure, function, and role in organic cation disposition.
Clin. Pharmacol. Ther.100 (5): 489-499. [PMID:27506881]
15. Wrighton DC, Muench SP, Lippiat JD. (2015)
Mechanism of inhibition of mouse Slo3 (KCa 5.1) potassium channels by quinine, quinidine and barium.
Br. J. Pharmacol.172 (17): 4355-63. [PMID:26045093]
16. Yamagishi T, Ishii K, Taira N. (1995)
Antiarrhythmic and bradycardic drugs inhibit currents of cloned K+ channels, KV1.2 and KV1.4.
Eur. J. Pharmacol.281 (2): 151-9. [PMID:7589202]
17. Yang B, Gribkoff VK, Pan J, Damagnez V, Dworetzky SI, Boissard CG, Bhattacharjee A, Yan Y, Sigworth FJ, Kaczmarek LK. (2006)
Pharmacological activation and inhibition of Slack (Slo2.2) channels.
Neuropharmacology51 (4): 896-906. [PMID:16876206]